Riskpilot← Back to searchSign inGet full accessBCC PharmaBase AB
ABActiveOrg 5592247174Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2025
—
EBITDA margin
—
+47% vs 2024
Equity ratio
99.4%
Financial strength
Net profit 2025
SEK 774K
+60% vs 2024
| Revenue | — | — |
| EBITDA | SEK -13K | +47% |
| Net profit | SEK 774K | +60% |
| Total assets | SEK 852K | +56% |
| Equity | SEK 847K | +59% |
| Employees | 0 | — |
Legal name
BCC PharmaBase AB
Org number
5592247174
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 oktober 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Äga och förvalta fast och lös egendom inom läkemedelsbranschen.
Address
Email
birgitta.ekstrom11@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | −10 | −5 | −7 | −25 | −13 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −10 | −5 | −7 | −25 | −13 |
| Net financials | — | 372 | 1 | 509 | 787 |
| Profit before tax | −10 | 367 | −5 | 485 | 774 |
| Tax | −0 | — | — | — | — |
| Net profit | −10 | 367 | −5 | 485 | 774 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 36 | 403 | 48 | 545 | 852 |
| Equity | 36 | 403 | 48 | 533 | 847 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 0 | 0 | — | 12 | 5 |
| Total debt | — | — | — | 12 | 5 |
EBITDA margin
-1306300.0%
This company
15.8%
Market median
-8267822% vs market
20212025
Equity ratio
99.4%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
91.4%
This company
18.4%
Market median
+397% vs market
20212025
Net profit margin
77418400.0%
This company
8.1%
Market median
+955782616% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CB Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BCC PharmaBase AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carin Birgitta Ekström | Chief Executive Officer | 0 companies |
| Christian Hans Fredrik Ekström | Deputy Board Member | 0 companies |
| Charlotte Hedvig Louise Ekström | Deputy Board Member | 0 companies |